DIABETES CARE & DEVICES

Diabetic Patient Unmet Device Usability & Treatment Adherence Support Survey

Diabetic patients evaluate, compare, and navigate device usability, dosing complexity, and adherence support gaps across their treatment journey, so you can sharpen product positioning, fix retention drop-offs, and benchmark support conversion.

Pan-India sample
Diabetic patients (Active Device Users)
15-20 min
Talk to a Survey Consultant
Usability friction & drop-offsIdentify where patients abandon devices due to handling, dosing, or discomfort barriers.
Adherence drivers & segmentationMap adherence patterns across patient segments by device type and support access.
TRUSTED BY LEADING BRANDS
Brand 0Brand 1Brand 2Brand 3Brand 4Brand 5Brand 6Brand 7Brand 8Brand 9Brand 10Brand 11Brand 12Brand 13Brand 14Brand 15Brand 16Brand 17Brand 18Brand 19Brand 20Brand 21Brand 22Brand 23Brand 24Brand 25Brand 26Brand 27Brand 28Brand 29Brand 30Brand 31

CONTEXT & RELEVANCE

Why run this survey now

Most diabetes device teams don't lose adherent patients purely on clinical efficacy. They lose them due to device handling friction, confusing titration guidance, inadequate onboarding support, poor hypoglycemia confidence, and misaligned refill touchpoints, none of which fully show up in prescription data or post-market surveillance reports.

If you are...

  • CGM or insulin pen manufacturer
  • Digital therapeutics platform lead
  • Device portfolio strategy head
  • Patient support program director
  • Commercial diabetes franchise lead

You're likely facing...

  • Device abandonment: onboarding vs. long-term
  • Usability gap: prescribed vs. actual use
  • Support channel mismatch: HCP vs. digital
  • Adherence drop: titration complexity barrier
  • Switching triggers: device vs. therapy dissatisfaction

This will help answer...

  • Top usability friction by device type
  • Adherence drop-off stage and trigger
  • Support need by patient segment
  • Willingness to pay for support
  • Switching drivers across device categories

RESEARCH THEMES

What This Survey Investigates

Eight interconnected research themes that map the complete diabetic patient journey from diagnosis to sustained self-management.

TENETS 01

Device Discovery

  • First device category encountered
  • Prescriber vs. self-initiated adoption
TENETS 02

Usability Gaps

  • Physical handling friction points
  • Display, alert, and readability issues
TENETS 03

Adherence Barriers

  • Missed dose and monitoring triggers
  • Lifestyle conflict with regimen
TENETS 04

Support Deficits

  • HCP contact frequency vs. need
  • Digital coaching and educator access
TENETS 05

Data & Connectivity

  • App integration and sync reliability
  • Glucose data sharing with care team
TENETS 06

Cost & Coverage

  • Out-of-pocket device and consumable spend
  • Insurance reimbursement gaps
TENETS 07

Switching & Loyalty

  • Device brand switch triggers
  • Retention drivers post-switch
TENETS 08

Outcome Perception

  • Self-reported glycaemic control confidence
  • Device impact on quality of life

SAMPLING STRATEGY

Tell us about your ideal sample

Help us understand your target respondent profile. Select what applies, we'll design the optimal sample plan based on your inputs.

Sample size
How many respondents do you need?
Not Selected
Target audience
Who should we survey?
Not Selected
Region
Which regions should we cover?
Not Selected
Segments
How should we slice the data?
Not Selected
Discuss sample plan

METHODOLOGY

Survey approach

For the Diabetic Patient Unmet Device Usability and Treatment Adherence Support Survey, we recommend a quant-first design with flexible data-collection modes to balance reach, depth, and verification.

PRIMARY
Online web surveySelf-administered survey shared via email / panels to capture structured responses at scale.
Best for
1
Measuring device usability friction by diabetes type
2
Ranking adherence barriers across therapy regimens
3
Comparing support gaps by patient segment and geography
Deliverables
Barrier priority ranking
Usability gap matrix
Adherence segment profiles
OPTIONAL
CATI (phone survey)Interviewer-led telephone interviews to reach owners who are harder to get online.
Best for
1
Older or low-digital patients with insulin devices
2
Reaching rural diabetic cohorts across multiple geographies
Deliverables
Rural patient coverage
Call-log diagnostics
SELECTIVE
Face-to-faceOn-ground surveys or interviews in key industrial clusters or high-value cohorts.
Best for
1
High-complexity patients on multi-device therapy regimens
2
Contextual device handling observation in clinic settings
Deliverables
Device interaction maps
Clinic-level insights
OPTIONAL
FGDs
Deliverables
Themes and quotes
Concept feedback
OPTIONAL
Mixed surveysAny 4-mode combo Online + CATI + F2F + FGDs to maximise reach and representation. Mode-specific quotas and weighting for clean comparisons.
Deliverables
Unified dataset
Mode-adjusted analytics
Our Recommendation
Start with: Online web survey as the core quant layer, targeting digitally active diabetic patients across Type 1, Type 2, and insulin-dependent segments to map device usability gaps and adherence drop-off points at scale.
Consider adding: CATI for older and rural patient cohorts with low digital access, and F2F interviews for high-complexity therapy patients where device handling observation and sensitive adherence disclosures require an in-person setting.

EXECUTION PROCESS

How we execute

A proven 9-step process from scoping to delivery, designed to ensure quality, speed, and actionable insights.

Define the decision frame

Confirm objectives, target cohorts, geographies, and reporting cuts

Step 01

Define the decision frame

Design the instrument

Build workstream modules mapped to outputs (drivers, friction, pricing, retention, trust)

Step 02

Design the instrument

Lock the questionnaire

Review wording, sequencing, LOI, and competitive context; approve final version

Step 03

Lock the questionnaire

Pilot and calibrate

Test comprehension and ease quality; refine quotas and remove friction where needed

Step 04

Pilot and calibrate

Run fieldwork

Execute collection with active quota management and feasibility controls

Step 05

Run fieldwork

Assure quality

Dedupe, attention checks, speed/consistency rules, removals with audit trail

Step 06

Assure quality

Prepare the dataset

Clean data and deliver codebook/variable definitions

Step 07

Prepare the dataset

Analyse and synthesise

Driver ranking, leakage diagnostics, pricing bands, segment insights

Step 08

Analyse and synthesise

Deliver and align

Executive deck (optional dashboard) and leadership readout with recommendations

Step 09

Deliver and align

COMMERCIAL TERMS

Request a Commercial Proposal

Pricing depends on cohort, geography, sample size, approach, LOI, and deliverables. Configure below for an indicative estimate.

Select Sample Size

100

Geography

  • India
  • APAC (Singapore, Vietnam, Philippines, Indonesia, Australia, NZ, Japan, Thailand)
  • Middle East (UAE, KSA, Qatar, Bahrain, Oman, Kuwait)
  • North America (US, Canada)
  • Europe
  • Africa (South Africa, Kenya, Nigeria, Egypt, Algeria)
  • LATAM (Brazil, Mexico)

Select Mode of Survey

  • Online
  • CATI
  • Online FGD (5 people per FGD)
  • F2F

Length of the Interview

  • Select
  • 0-15
  • 16-20
  • 21-30
  • 31-45
  • 46-60
  • Custom
Indicative Estimate
  • Indian Rupee (INR)
  • United Arab Emirates Dirham (AED)
  • Afghan Afghani (AFN)
  • Albanian Lek (ALL)
  • Armenian Dram (AMD)
  • Netherlands Antillean Guilder (ANG)
  • Angolan Kwanza (AOA)
  • Argentine Peso (ARS)
  • Australian Dollar (AUD)
  • Aruban Florin (AWG)
  • Azerbaijani Manat (AZN)
  • Bosnia-Herzegovina Convertible Mark (BAM)
  • Barbadian Dollar (BBD)
  • Bangladeshi Taka (BDT)
  • Bulgarian Lev (BGN)
  • Bahraini Dinar (BHD)
  • Burundian Franc (BIF)
  • Bermudian Dollar (BMD)
  • Brunei Dollar (BND)
  • Bolivian Boliviano (BOB)
  • Brazilian Real (BRL)
  • Bahamian Dollar (BSD)
  • Bhutanese Ngultrum (BTN)
  • Botswana Pula (BWP)
  • Belarusian Ruble (BYN)
  • Belize Dollar (BZD)
  • Canadian Dollar (CAD)
  • Congolese Franc (CDF)
  • Swiss Franc (CHF)
  • Chilean Peso (CLP)
  • Chinese Yuan (CNY)
  • Colombian Peso (COP)
  • Costa Rican Colón (CRC)
  • Cuban Peso (CUP)
  • Cape Verdean Escudo (CVE)
  • Czech Koruna (CZK)
  • Djiboutian Franc (DJF)
  • Danish Krone (DKK)
  • Dominican Peso (DOP)
  • Algerian Dinar (DZD)
  • Egyptian Pound (EGP)
  • Eritrean Nakfa (ERN)
  • Ethiopian Birr (ETB)
  • Euro (EUR)
  • Fijian Dollar (FJD)
  • Falkland Islands Pound (FKP)
  • British Pound (GBP)
  • Georgian Lari (GEL)
  • Ghanaian Cedi (GHS)
  • Gibraltar Pound (GIP)
  • Gambian Dalasi (GMD)
  • Guinean Franc (GNF)
  • Guatemalan Quetzal (GTQ)
  • Guyanese Dollar (GYD)
  • Hong Kong Dollar (HKD)
  • Honduran Lempira (HNL)
  • Croatian Kuna (HRK)
  • Haitian Gourde (HTG)
  • Hungarian Forint (HUF)
  • Indonesian Rupiah (IDR)
  • Israeli New Shekel (ILS)
  • Iraqi Dinar (IQD)
  • Iranian Rial (IRR)
  • Icelandic Króna (ISK)
  • Jamaican Dollar (JMD)
  • Jordanian Dinar (JOD)
  • Japanese Yen (JPY)
  • Kenyan Shilling (KES)
  • Kyrgyzstani Som (KGS)
  • Cambodian Riel (KHR)
  • Comorian Franc (KMF)
  • South Korean Won (KRW)
  • Kuwaiti Dinar (KWD)
  • Cayman Islands Dollar (KYD)
  • Kazakhstani Tenge (KZT)
  • Lao Kip (LAK)
  • Lebanese Pound (LBP)
  • Sri Lankan Rupee (LKR)
  • Liberian Dollar (LRD)
  • Lesotho Loti (LSL)
  • Libyan Dinar (LYD)
  • Moroccan Dirham (MAD)
  • Moldovan Leu (MDL)
  • Malagasy Ariary (MGA)
  • Macedonian Denar (MKD)
  • Burmese Kyat (MMK)
  • Mongolian Tögrög (MNT)
  • Macanese Pataca (MOP)
  • Mauritian Rupee (MUR)
  • Maldivian Rufiyaa (MVR)
  • Malawian Kwacha (MWK)
  • Mexican Peso (MXN)
  • Malaysian Ringgit (MYR)
  • Mozambican Metical (MZN)
  • Namibian Dollar (NAD)
  • Nigerian Naira (NGN)
  • Nicaraguan Córdoba (NIO)
  • Norwegian Krone (NOK)
  • Nepalese Rupee (NPR)
  • New Zealand Dollar (NZD)
  • Omani Rial (OMR)
  • Panamanian Balboa (PAB)
  • Peruvian Sol (PEN)
  • Papua New Guinean Kina (PGK)
  • Philippine Peso (PHP)
  • Pakistani Rupee (PKR)
  • Polish Złoty (PLN)
  • Paraguayan Guaraní (PYG)
  • Qatari Riyal (QAR)
  • Romanian Leu (RON)
  • Serbian Dinar (RSD)
  • Russian Ruble (RUB)
  • Rwandan Franc (RWF)
  • Saudi Riyal (SAR)
  • Solomon Islands Dollar (SBD)
  • Seychellois Rupee (SCR)
  • Sudanese Pound (SDG)
  • Swedish Krona (SEK)
  • Singapore Dollar (SGD)
  • Saint Helena Pound (SHP)
  • Sierra Leonean Leone (SLL)
  • Somali Shilling (SOS)
  • Surinamese Dollar (SRD)
  • São Tomé and Príncipe Dobra (STD)
  • Syrian Pound (SYP)
  • Swazi Lilangeni (SZL)
  • Thai Baht (THB)
  • Tajikistani Somoni (TJS)
  • Turkmenistani Manat (TMT)
  • Tunisian Dinar (TND)
  • Tongan Paʻanga (TOP)
  • Turkish Lira (TRY)
  • Trinidad and Tobago Dollar (TTD)
  • New Taiwan Dollar (TWD)
  • Tanzanian Shilling (TZS)
  • Ukrainian Hryvnia (UAH)
  • Ugandan Shilling (UGX)
  • United States Dollar (USD)
  • Uruguayan Peso (UYU)
  • Uzbekistani Som (UZS)
  • Vietnamese Đồng (VND)
  • Vanuatu Vatu (VUV)
  • Samoan Tālā (WST)
  • Central African CFA Franc (XAF)
  • East Caribbean Dollar (XCD)
  • West African CFA franc (XOF)
  • CFP Franc (XPF)
  • Yemeni Rial (YER)
  • South African Rand (ZAR)
  • Zambian Kwacha (ZMW)
  • Zimbabwean Dollar (ZWL)

$0.00

+ applicable taxes

Proposal turnaround typically 24–48 hours

Note: Estimate is indicative only. Final pricing is subject to scope finalization after discovery call.

REFERENCE CASELETS

Reference

Real-world examples of survey work in the chronic disease device and adherence space.

CASELET 1

Insulin delivery device friction & segment preference map (India)

CASELET 2

CGM adoption messaging & HCP channel levers (South Asia)

Insulin delivery device friction & segment preference map (India)

OBJECTIVE

A specialty pharma client needed to isolate why insulin-dependent Type 2 patients across metro, Tier 1, and Tier 2 geographies switched between pen devices and vials , and which usability barriers drove early discontinuation within the first 90 days of prescription.

WHAT WE DID

Ran a structured quant survey across 480 patients, capturing device handling confidence, injection site discomfort, dose-setting legibility, refill access friction, and HCP instruction adequacy at initiation, segmented by treatment duration and prescriber channel.

DELIVERED

A usability friction map by device type and patient segment, a ranked barrier list across the first 90-day window, and a segment preference framework separating self-managing patients from caregiver-dependent users by geography and literacy level.
CASELET 1

Insulin delivery device friction & segment preference map (India)

CASELET 2

CGM adoption messaging & HCP channel levers (South Asia)

Insulin delivery device friction & segment preference map (India)

OBJECTIVE

A specialty pharma client needed to isolate why insulin-dependent Type 2 patients across metro, Tier 1, and Tier 2 geographies switched between pen devices and vials , and which usability barriers drove early discontinuation within the first 90 days of prescription.

WHAT WE DID

Ran a structured quant survey across 480 patients, capturing device handling confidence, injection site discomfort, dose-setting legibility, refill access friction, and HCP instruction adequacy at initiation, segmented by treatment duration and prescriber channel.

DELIVERED

A usability friction map by device type and patient segment, a ranked barrier list across the first 90-day window, and a segment preference framework separating self-managing patients from caregiver-dependent users by geography and literacy level.

FREQUENTLY ASKED QUESTIONS

Common Questions

Answers to frequently asked questions about this survey mandate.

What decisions will this survey enable?

Who is the buyer vs who are the respondents?

Can we see differences between insulin-dependent patients, non-insulin oral therapy patients and newly diagnosed patients?

How will you measure device usability preference beyond simple ratings?

Will the survey map the full diabetes device and therapy adherence journey and drop-offs?

Can this survey inform product and pricing strategy?

How will findings improve our patient retention and commercial launch strategy?

Still have questions?

Schedule a discovery call to discuss your specific needs and get a custom quote.

Book a Discovery Call